| scholarly article | Q13442814 |
| P50 | author | Frits van Rhee | Q42540710 |
| P2093 | author name string | Q Zhang | |
| J D Shaughnessy | |||
| B Nair | |||
| J Crowley | |||
| B Barlogie | |||
| T Milner | |||
| C J Heuck | |||
| E Hansen | |||
| A Hoering | |||
| J Sawyer | |||
| N Petty | |||
| S Waheed | |||
| P Qu | |||
| R Sexton | |||
| Z Singh | |||
| J Szymonifka | |||
| S Z Usmani | |||
| Y Alsayed | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Primary plasma cell leukaemia | Q33490175 | ||
| Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance | Q33887470 | ||
| The molecular classification of multiple myeloma | Q34530992 | ||
| International uniform response criteria for multiple myeloma. | Q34549410 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 | Q35266125 | ||
| Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma | Q35848236 | ||
| Plasma cell leukemia: an evaluation of response to therapy | Q39725181 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 | ||
| Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. | Q50538038 | ||
| A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. | Q53246749 | ||
| Plasma cell leukemia. Report on 17 cases | Q53817942 | ||
| Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 | Q80530381 | ||
| P433 | issue | 11 | |
| P921 | main subject | leukemia | Q29496 |
| plasma cell leukemia | Q7201765 | ||
| P304 | page(s) | 2398-2405 | |
| P577 | publication date | 2012-04-17 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols | |
| P478 | volume | 26 |
| Q104567525 | Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial |
| Q36331788 | Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents |
| Q38564926 | Defining and treating high-risk multiple myeloma |
| Q90428497 | European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias |
| Q33401759 | Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents |
| Q91497066 | Extramedullary multiple myeloma |
| Q96576366 | Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns |
| Q92094177 | Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era |
| Q54458683 | Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal. |
| Q38979403 | High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges |
| Q33402555 | How I treat plasma cell leukemia |
| Q44404066 | Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia |
| Q55498024 | MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. |
| Q26799238 | Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine |
| Q58780167 | PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism |
| Q35207033 | Plasma cell leukaemia: a management conundrum |
| Q33956990 | Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group |
| Q52838137 | Plasma cell leukemia: update on biology and therapy. |
| Q38781794 | Primary Plasma Cell Leukemia: Identity Card 2016. |
| Q30243927 | Primary plasma cell leukemia 2.0: advances in biology and clinical management. |
| Q37746021 | Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia |
| Q34173892 | Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. |
| Q52663601 | Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. |
| Q59129093 | Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma |
| Q47140962 | The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). |
| Q91361821 | Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background |
| Q34019590 | Trends in survival of patients with primary plasma cell leukemia: a population-based analysis |
Search more.